AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

AngioDynamics reports robust Q2 growth driven by key products

AngioDynamics delivered strong financial results driven by key product growth, reaffirming confidence in guidance and market stability.
Strategic focus on innovation, clinical trials, and global expansion positions the company for long-term success and market leadership.
Challenges in certain business segments require attention, but opportunities in new product releases and market expansion offer growth potential.
Overall, AngioDynamics remains committed to platform technologies and being a trusted care delivery partner, ensuring a strong strategic position in the market.

AngioDynamics reports Q3 growth, navigates challenges, eyes new opportunities

AngioDynamics showed solid revenue growth in Q3 2023, led by the Med Tech segment despite challenges with AngioVac.
The company is focused on addressing sales declines, exploring new product potentials, and maintaining cash flow neutrality.
Opportunities lie in new product usage trends, potential market expansions, and commitment to growth and profitability globally.
Despite revised guidance, AngioDynamics remains resilient in navigating challenges and pursuing strategic opportunities for future growth.

AngioDynamics posts solid earnings, eyes growth through innovation and markets

AngioDynamics delivered strong financial performance in Q4 2023 and FY '23, driven by growth in key segments and international markets.
The company's strategic focus on core businesses and favorable legal outcomes position it for future growth.
Challenges include projected losses for FY '24 and the need to boost Med Device revenue growth.
Opportunities lie in product innovation, clinical study outcomes, and market expansion initiatives.

AngioDynamics reports Q1 growth, eyes innovation amid investor concerns

AngioDynamics' Q1 performance reflects mixed results with revenue growth but losses per share, driven by strong segments like NanoKnife.
The company's financial position remains stable with healthy cash reserves and a positive outlook for future cash flow and revenue growth.
Challenges lie in balancing declining segments like mechanical thrombectomy with growth opportunities in new treatment areas and investor relations.
Opportunities for growth exist through innovation in the Auryon platform, potential indications from the APEX PE study, and strategic investor engagement.
AngioDynamics navigates a complex landscape of growth and challenges, focusing on innovation and financial stability amidst investor concerns.

AngioDynamics reports Q2 growth, navigates challenges with strategic initiatives

AngioDynamics delivered steady revenue growth in Q2 2024, driven by international expansion and strong performance in key segments.
While facing challenges in certain businesses, the company is strategically restructuring operations and investing in innovation for future growth.
Opportunities lie in expanding Auryon's market reach, optimizing manufacturing processes, and maintaining a focus on cost efficiency.
Overall, AngioDynamics is navigating challenges while positioning itself for long-term success through strategic initiatives and product enhancements.

AngioDynamics reports strong Q3 growth, eyes global expansion opportunities

AngioDynamics demonstrated solid revenue growth and strategic milestones in Q3 2024, with a focus on product innovation and international expansion.
While facing challenges in certain business segments, the company's regulatory successes and financial stability position it well for future growth.
Opportunities in upcoming data releases and market trends present avenues for AngioDynamics to capitalize on its strengths and drive further success.

AngioDynamics reports Q4 growth, eyes revenue expansion in 2025

AngioDynamics delivered a mixed performance in Q4 2024 with growth in Med Tech segment but declines in mechanical thrombectomy and Med Device segments.
Despite challenges, the company managed to generate excess cash flow and narrow its adjusted EBITDA loss, showcasing financial resilience.
Future opportunities lie in revenue growth projections for fiscal year 2025 and strategic initiatives aimed at market expansion and optimization.

AngioDynamics reports modest revenue growth and progresses towards profitability

AngioDynamics demonstrated overall growth in revenue and progress towards profitability in Q1 2025. While facing challenges with NanoKnife revenue and profitability, the company's Med Tech segment showed strength with Auryon and AlphaVac. Opportunities lie in cost savings from outsourced manufacturing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is scheduled to participate in the following upcoming investor conferences: 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Date: August 12, 2024 Canaccord Genuity 44th.

AngioDynamics to Participate in Upcoming Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know

First United Corp.

Hagerty

Kronos Worldwide

PROG Holdings

KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.

New Strong Buy Stocks for July 29th

AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife generated double-digit year-over-year growth, while AlphaVac bounced back strongly on a sequential basis, and gross margin improved more than three points. Execution remains the key here, as Auryon, AlphaVac, and NanoKnife all have legitimate growth potential, but significant competition as well.

AngioDynamics: Lumpy Progress Is Still Progress

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

AngioDynamics Inc. (NASDAQ:ANGO ) Q4 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steve Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics fiscal year 2024 Fourth Quarter Earnings Call.

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago.

AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024. Fiscal Year 2024 Fourth Quarter Highlights   Quarter Ended May 31, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $71.1.

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2024 before the market open on Tuesday, July 16, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day t.

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE). “The CE Mark represents a major.

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hos.

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful.

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mode.

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support catheter products, to further streamline its product portfolio   GAAP As Reported Pro Forma* Net Sales: $75.2 million $66.0 million Growth: N/A 8.0% Gross Margin 47.7% 51.1% GAAP Loss per Sh.

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE. PE affect.

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

AngioDynamics (ANGO) Settles Patent Litigations With BD

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. Under the terms of the settlement, BD.

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to.

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.

AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors

In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.

News for AngioDynamics Stock (ANGO)